Lymphoma

Russell Ryan, M.D., an assistant professor in the Department of Pathology at the University of Michigan Medical School and a member of the University of Michigan Health Rogel Cancer Center, and his team used a method called ChIP-Seq to map the regulatory elements that control gene expression in B-cell lymphomas, a cancer of the immune system, in sample B-cell cancer cell lines.

In early research led by the University of Michigan Health Rogel Cancer Center, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone lymphoma. Cancers shrunk in 80% of the 20 patients on the clinical trial with marginal zone lymphoma, with a fifth experiencing complete remission.

STAT3 has been a major therapeutic target in the treatment of cancer. But it's largely been considered “undruggable” due to the difficulty of developing compounds to effectively inhibit its activity. Researchers at the U-M Rogel Cancer Center have a new approach to targeting STAT3.